# New Publication in Vaccine Highlights Preclinical Results of Vaxart's Mucosal Chikungunya Vaccine

May 29, 2019

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 29, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, *Vaccine.*

The article, titled "*An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling,*" details the results from a study using Vaxart's chikungunya vaccine candidate in a preclinical efficacy model.

"These preclinical results demonstrate that our vaccine candidate induced significant neutralizing antibodies against chikungunya virus as well as protective efficacy against virus-induced pathologic changes," said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart. "Importantly, we saw reduced footpad swelling, a model for arthritis induction in humans caused by chikungunya infection. There are no approved vaccines or treatments for the estimated one million patients each year infected with chikungunya virus."

Vaxart develops oral vaccines for a broad range of infections that have a major impact on public health, including vaccines for norovirus and influenza.

**About Chikungunya**

Chikungunya is an illness caused by a virus that spreads through mosquito bites. The most common symptoms of chikungunya are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. The mosquito that carries chikungunya virus bites primarily during the daytime, both indoors and outdoors, and often lives around buildings in urban areas. Patients symptoms usually begin 3—7 days after being bitten by an infected mosquito. Most patients will feel better within a week. In some people, the joint pain may persist for months. Death is rare. People at risk for more severe disease include newborns infected around the time of birth, older adults (≥65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease. Travelers who go to Africa, Asia, parts of Central and South America, and islands in the Indian Ocean, Western and South Pacific, and Caribbean are at risk.

**About Vaxart**

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart's vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart's vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart's development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).

**Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "believe," "could," "potential," "will" and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to the Vaxart's ability to develop and commercialize its product candidates and clinical results and trial data; the expected timing of the initiation of the Phase 1 bivalent study and Phase 2 monovalent challenge study; and Vaxart's expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that Vaxart may experience manufacturing issues and delays; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005267/en/

Source: Vaxart, Inc.

Daniella Funaro
Stern Investor Relations
212-362-1200
vaxart@sternir.com